Prospective screening for ALK: Clinical features and outcome according to ALK status

详细信息    查看全文

• 作者：Vincent Fallet^a ; ^b ; Jacques Cadranel^a ; ^b ; Hé ; lè ; ne Doubre^c ; Cé ; cile Toper^b ; Isabelle Monnet^d ; Thierry Chinet^e ; Gé ; rard Oliviero^f ; Guillaume Foulon^g ; Hubert De Cremoux^h ; Thibault Vieira^a ; Martine Antoine^a ; ⁱ ; Marie Wislez^a ; ^b ; ^{marie.wislez@tnn.aphp.fr" class="auth_mail}
• 关键词：Lung neoplasms ; Non-small-cell lung ; EML4-ALK fusion protein ; Adenocarcinoma ; Crizotinib ; Survival analysis
• 刊名：European Journal of Cancer
• 出版年：May, 2014
• 年：2014
• 卷：50
• 期：7
• 页码：1239-1246
• 全文大小：512 K

文摘

The aim of this study was to analyse the clinico-pathological characteristics and outcomes of a cohort of French patients who were prospectively screened for Anaplastic Lymphoma Kinase (ALK) rearrangement.

One hundred and sixteen consecutive patients screened for ALK rearrangement to be recruited into a crizotinib registration trial were included from eight French centres. ALK rearrangement was detected by fluorescence in situ hybridization.

Seventeen patients (14.6%) were positive for ALK. ALK+ patients were younger (p = 0.049) and more likely to be males (p = 0.032), non- or light-smokers (p = 0.048) and without underlying respiratory disease (p = 0.025) compared to ALK鈭?patients. Thyroid-transcription factor-1 expression was present in all ALK+ tumours. ALK+ tumours tended to have lymph node and brain metastases. In multivariate analyses, gender, smoking history and N stage were independently associated with ALK status. Median overall survival (OS) was not reached for ALK+ patients and was significantly longer than for ALK鈭?patients (hazard ratio for death for ALK鈭?patients 2.98; 95% CI [1.29-6.90], p = 0.01).

French ALK+ patients present a specific phenotype. ALK rearrangement should be determined to improve OS with an effective targeted therapy.